The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein Thus, the solid oral dosage form provides an in vivo plasma pridopidine concentration profile with an average Cmax of about 1,400 ng / ml or less. The subject invention also provides a method of treating an individual suffering from a neurodegenerative disease or a disease related to dopamine, comprising once daily administration of a controlled release solid oral dosage form.主題発明は、治療上有効量のプリドピジンまたはその薬学的に許容し得る塩、および少なくとも１種の薬学的に許容し得る速度制御賦形剤を含む、調節放出固形経口剤形を提供し、ここで、固形経口剤形は、約１，４００ｎｇ／ｍｌ以下の平均Ｃmaxを有するインビボ血漿プリドピジン濃度特性をもたらす。主題発明はまた、調節放出固形経口剤形の１日１回の投与を含む、神経変性疾患またはドーパミンに関連する疾患を患っている個体を処置する方法も提供する。
